



**A Progression-Free Survival**



|                     | CRS1/2,<br>BRCA1/2(+) | CRS1/2,<br>BRCA1/2(-) | CRS3,<br>BRCA1/2(+) | CRS3,<br>BRCA1/2(-) |
|---------------------|-----------------------|-----------------------|---------------------|---------------------|
| Events              | 14 (46.7%)            | 48 (66.7%)            | 7 (46.7%)           | 19 (52.8%)          |
| Median PFS (months) | 26.8                  | 17.5                  | 29.2                | 26.5                |
| 95% CI              | 21.1-32.5             | 14.6-20.3             | 19.4-38.9           | 17.1-3              |

**B Overall Survival**



|                    | CRS1/2,<br>BRCA1/2(+) | CRS1/2,<br>BRCA1/2(-) | CRS3,<br>BRCA1/2(+) | CRS3,<br>BRCA1/2(-) |
|--------------------|-----------------------|-----------------------|---------------------|---------------------|
| Events             | 3 (10.0%)             | 17 (23.6%)            | 0 (0%)              | 2 (5.6%)            |
| Median OS (months) | Not reached           | 96.4                  | Not reached         | Not reached         |
| 95% CI             | -                     | -                     | -                   | -                   |